AdaptHealth Posts $154M Q3 Loss on $184.8M Goodwill Impairment; Free Cash Flow Collapses
AHCO sits 21% above its 52-week low of $5.21 on elevated volume (2.7× avg).
Summary
Revenue rose 10.9% to $745.6M in Q3, but a $184.8M non-cash goodwill impairment drove a $154M net loss, and nine-month free cash flow fell to $2.6M from $140.1M on heavy equipment spending.
Key Events · Earnings and Guidance · AHCO
-
Q3 Revenue Up 10.9%, Net Loss $154M
Net revenue rose to $745.6M from $672.4M, but the quarter produced a net loss of $153.99M, or $1.13 per basic share, versus $0.17 of income a year earlier.
-
$184.8M Non-Cash Goodwill Impairment
A sustained stock price decline triggered a quantitative test; Respiratory Health was written down $149.4M and Wellness at Home $35.4M. Nine-month impairment totals $329.0M. Sleep Health passed, but its fair value cushion over carrying value is under 20%.
-
Free Cash Flow Falls to $2.6M
Nine-month free cash flow dropped to $2.6M from $140.1M as purchases of equipment and other fixed assets rose to $393.0M from $278.5M, largely to support capitated revenue arrangements.
-
Liquidity Tightens Ahead of Diabetes Sale
Cash stood at $80.7M with negative working capital of $82.3M and $1.88B of debt; the $235.0M Diabetes Health sale is expected to close in Q1 2027 subject to regulatory approvals.
Analysis · AHCO · Industrial Applications And Services
Revenue grew 10.9% to $745.6M, yet the quarter ended in a $154M net loss after a $184.8M non-cash goodwill impairment on the Respiratory Health and Wellness at Home units, triggered by the sustained decline in the share price. The cash story is the real problem: nine-month free cash flow fell to $2.6M from $140.1M a year ago as capital spending on patient equipment jumped to $393.0M to support new at-risk capitated contracts. With only $80.7M of cash, negative working capital of $82.3M and $1.88B of debt, the $235M Diabetes Health sale — now expected to close in Q1 2027 — is the main lever to shore up the balance sheet. The filing also flags an October 2026 Medline field action pulling all Medline brand beds from the market, a new supply constraint.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AHCO was trading at $6.28 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $856.2M. The 52-week trading range was $5.21 to $13.43. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.